ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2155

Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink

Alicia Gayle1, Nils Schoof2, Margarida Alves2, Deborah Clarke3, Chris Poole1, Christina Raabe2, Prithwiraj Das1 and Toby Maher4, 1Boehringer Ingelheim Ltd., Bracknell, United Kingdom, 2Boehringer Ingelheim International GmbH, Ingelheim, Germany, 3Department of Medical Affairs, Boehringer Ingelheim Ltd., Bracknell, United Kingdom, 4University College London and Royal Brompton Hospital, London, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Clinical practice, cross-sectional studies, diagnosis, interstitial lung disease and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease that is characterised by fibroblast dysfunction and excess extracellular matrix deposition that leads to skin thickening and internal organ damage. Patients with SSc often develop interstitial lung disease (ILD) which is currently the leading cause of death. The burden of SSc in the UK is currently unknown. However, it is reported that a high proportion of patients present with advanced disease at diagnosis. The reasons for late diagnosis in SSc are not fully understood, although different routes to diagnosis have been associated with differences in survival. This study aimed to investigate patient characteristics related to first SSc diagnosis in hospital, compared to primary care.

Methods: We carried out a population-based cross-sectional study using data from the Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES). All adult patients with a diagnosis of SSc were identified using International Classification of Diseases-10-Clinical Modification diagnosis codes in hospital records and READ codes in primary care electronic records combined with an adapted version of the EULAR algorithm for defining SSc. Patients were classified into 3 groups: incident SSc, SSc with incident ILD (SSc-ILD), and SSc with other organ involvement (SSc-OOI). Source of diagnosis and patient characteristics were then described.

Results: The study included 606 individuals with incident diagnosis of SSc recorded in either CPRD or HES. Only 1% of patients had a diagnosis code in both primary care and secondary care records. 81% of the cohort were women and the average age at diagnosis was 61 (SD = 15). 20% of the cohort had SSc-ILD and 63% had SSc-OOI with an overlap of 15%. Patients first diagnosed with SSc in hospital presented higher rates of hospital visits and had a greater proportion of “red-flag” symptoms predictive of SSc (e.g. Raynaud’s or gastrointestinal reflux) prior to SSc diagnosis. Patients with an overlap of SSc-ILD and SSc-OOI tended to be overweight or obese.

Conclusion: Our results provide evidence of differences between patients diagnosed with SSc through UK primary care or secondary/tertiary care routes. These findings should inform the development of initiatives to improve earlier diagnosis of SSc.


Disclosure: A. Gayle, Boehringer Ingelheim, 3; N. Schoof, Boehringer Ingelheim, 3; M. Alves, Boehringer Ingelheim, 3; D. Clarke, Boehringer Ingelheim, 3; C. Poole, Boehringer Ingelheim, 3; C. Raabe, Boehringer Ingelheim, 3; P. Das, Boehringer Ingelheim, 3; T. Maher, GSK, 2, 5,UCB, 2, 5, 6,Boehringer Ingelheim, Astra Zeneca, Roche, Bayer, Biogen Idec, Cipla, Prometic, Sanumed, 5,Apellis, 1.

To cite this abstract in AMA style:

Gayle A, Schoof N, Alves M, Clarke D, Poole C, Raabe C, Das P, Maher T. Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/diagnosis-of-systemic-sclerosis-in-the-united-kingdom-an-observational-study-using-the-clinical-practice-research-datalink/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnosis-of-systemic-sclerosis-in-the-united-kingdom-an-observational-study-using-the-clinical-practice-research-datalink/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.